CMC Biologics

Founded in 1990, CMC ICOS Biologics aims at discovering, developing and marketing therapeutic products. CMC ICOS Biologics works toward developing treatments for medical conditions, such as benign prostatic hyperplasia, hypertension, pulmonary arterial hypertension, cancer and inflammatory diseases. The company has a joint venture with Eli Lilly and Company and markets its product Cialis for the treatment of erectile dysfunction. The company also manufactures Tadalafil for treating the enlargement of the prostate and IC485 chronic obstructive pulmonary disease. The company has expertise in cell line and process development and specializes in delivering protein-based materials and recombinant protein products for preclinical and clinical trials. CMC ICOS Biologics is headquartered in Bothell, Wash.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company based in Bothell, WA, specializing in the discovery and development of novel antiviral therapeutics. With a focus on targeting the replication process of various viruses, including SARS-CoV-2, influenza, norovirus, and hepatitis C, the company utilizes a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Driven by the global need for effective and safe antiviral treatments, Cocrystal Pharma is advancing multiple antiviral therapeutic candidates as quickly and efficiently as possible. Their development programs encompass a wide range of serious and chronic viral diseases, including influenza, COVID-19, hepatitis C, and gastroenteritis caused by norovirus. Through their targeted solutions for viral diseases, the company aims to combat the ongoing pandemic and seasonal influenza, as well as address other high-value indications.Generated from the website

Ondine Biomedical Inc. is a Canadian life sciences company that has emerged as a global leader in photodisinfection-based therapies for preventing and treating a wide range of infections, including those caused by drug-resistant pathogens. Their patented platform technology offers solutions for infections in healthcare and industrial settings, with recent studies demonstrating up to an 84% reduction in postoperative infection rates in major Canadian hospitals. Their flagship product, Steriwave, is a rapid nasal decolonization therapy that effectively eradicates a broad spectrum of pathogens in just minutes, significantly reducing the risk of healthcare-associated infections. Ondine Biomedical is dedicated to developing innovative products to combat antimicrobial resistance and improve patient outcomes, with a focus on safe, fast, and cost-effective solutions for complex infections. Generated from the website